PMID- 29258453 OWN - NLM STAT- MEDLINE DCOM- 20180723 LR - 20181113 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 17 IP - 1 DP - 2017 Dec 19 TI - Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study. PG - 867 LID - 10.1186/s12885-017-3861-9 [doi] LID - 867 AB - BACKGROUND: Preliminary evidence suggests that changes in plasma brain-derived neurotrophic factor (BDNF) levels may contribute to the occurrence of chemotherapy-associated cognitive impairment (CACI), and a previous study suggested that carriers of the BDNF Met homozygous genotype are protected from CACI. METHODS: This multicenter, prospective cohort study involved chemotherapy-receiving early-stage breast cancer (ESBC) patients. Self-perceived cognitive function was longitudinally assessed using the validated FACT-Cog (ver. 3) across three time points: Prior to chemotherapy (T1), during chemotherapy (T2), and at the end of chemotherapy (T3). Plasma BDNF levels were quantified using enzyme-linked immunosorbent assay. Genotyping was performed using Sanger Sequencing. RESULTS: A total of 51 chemotherapy-receiving ESBC patients (mean age: 52.6 +/- 9.5 years) were recruited, and 11 patients (21.6%) reported subjective cognitive impairment post-chemotherapy. Overall, there was a reduction in median plasma BDNF levels over time (T1: 5423.0 pg/ml; T2: 5313.6 pg/ml; T3: 4050.3 pg/ml; p < 0.01). After adjusting for confounding factors, longitudinal analysis revealed that BDNF levels were associated with self-reported concentration deficit (p = 0.032). Carriers of Val/Val (p = 0.011) and Val/Met (p = 0.003) BDNF genotypes demonstrated a significant reduction in plasma BDNF levels over time; however, plasma BDNF levels were similar across all time points among Met homozygous carriers (p = 0.107). CONCLUSION: There was a statistically significant change in BDNF levels post-chemotherapy in ESBC patients, and plasma BDNF levels were associated with self-perceived concentration deficit in patients receiving chemotherapy. FAU - Ng, Terence AU - Ng T AD - Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore. AD - Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore. FAU - Lee, Ying Yun AU - Lee YY AD - Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore. FAU - Chae, Jung-Woo AU - Chae JW AD - Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore. AD - Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore. FAU - Yeo, Angie Hui Ling AU - Yeo AHL AD - Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore. FAU - Shwe, Maung AU - Shwe M AD - Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore. FAU - Gan, Yan Xiang AU - Gan YX AD - Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore. FAU - Ng, Raymond C H AU - Ng RCH AD - Duke-NUS Medical School Singapore, Singapore, Singapore. AD - Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. FAU - Chu, Pat Pak Yan AU - Chu PPY AD - Singapore Cord Blood Bank, K.K. Women's and Children's Hospital, Singapore, Singapore. FAU - Khor, Chiea Chuen AU - Khor CC AD - Genome Institute of Singapore, Singapore, Singapore. FAU - Ho, Han Kiat AU - Ho HK AD - Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore. FAU - Chan, Alexandre AU - Chan A AD - Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4A, 18 Science Drive 4, Level 3, Singapore, 117543, Singapore. phaac@nus.edu.sg. AD - Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore. phaac@nus.edu.sg. AD - Duke-NUS Medical School Singapore, Singapore, Singapore. phaac@nus.edu.sg. LA - eng GR - NMRC/CIRG/1386/2014/National Medical Research Council/ PT - Journal Article DEP - 20171219 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Brain-Derived Neurotrophic Factor) RN - 7171WSG8A2 (BDNF protein, human) SB - IM MH - Adult MH - Aged MH - Brain-Derived Neurotrophic Factor/blood/*genetics MH - Breast Neoplasms/blood/*drug therapy/*genetics/pathology MH - Cognitive Dysfunction/chemically induced/pathology MH - Female MH - Genetic Association Studies MH - *Genetic Predisposition to Disease MH - Genotype MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Polymorphism, Single Nucleotide PMC - PMC5735945 OTO - NOTNLM OT - BDNF OT - Breast cancer OT - Cognition OT - Genetics OT - rs6265 COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Ethics approval by SingHealth Institutional Review Board was attained prior to the execution of the study. Patients have provided informed consent prior to enrollment in this study (CIRB 2014/754/B). CONSENT FOR PUBLICATION: All authors have provided consent for publication. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2017/12/21 06:00 MHDA- 2018/07/24 06:00 PMCR- 2017/12/19 CRDT- 2017/12/21 06:00 PHST- 2016/06/29 00:00 [received] PHST- 2017/11/29 00:00 [accepted] PHST- 2017/12/21 06:00 [entrez] PHST- 2017/12/21 06:00 [pubmed] PHST- 2018/07/24 06:00 [medline] PHST- 2017/12/19 00:00 [pmc-release] AID - 10.1186/s12885-017-3861-9 [pii] AID - 3861 [pii] AID - 10.1186/s12885-017-3861-9 [doi] PST - epublish SO - BMC Cancer. 2017 Dec 19;17(1):867. doi: 10.1186/s12885-017-3861-9.